AR078929A1 - Composicion que comprende un ester de un prostanoide y un acido carboxilico. metodo para conferir estabilidad acuosa a la anterior y su uso para preparar un medicamento util para tratar un trastorno ocular - Google Patents
Composicion que comprende un ester de un prostanoide y un acido carboxilico. metodo para conferir estabilidad acuosa a la anterior y su uso para preparar un medicamento util para tratar un trastorno ocularInfo
- Publication number
- AR078929A1 AR078929A1 ARP100104122A ARP100104122A AR078929A1 AR 078929 A1 AR078929 A1 AR 078929A1 AR P100104122 A ARP100104122 A AR P100104122A AR P100104122 A ARP100104122 A AR P100104122A AR 078929 A1 AR078929 A1 AR 078929A1
- Authority
- AR
- Argentina
- Prior art keywords
- composition
- prostanoid
- ester
- alkyl
- treat
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 10
- 229940127293 prostanoid Drugs 0.000 title abstract 5
- 150000003814 prostanoids Chemical class 0.000 title abstract 5
- 208000030533 eye disease Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title abstract 2
- 239000002253 acid Substances 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 239000000556 agonist Substances 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 150000001735 carboxylic acids Chemical class 0.000 abstract 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 208000010412 Glaucoma Diseases 0.000 abstract 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000004406 elevated intraocular pressure Effects 0.000 abstract 2
- 150000002148 esters Chemical class 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 2
- 125000005429 oxyalkyl group Chemical group 0.000 abstract 2
- 239000002904 solvent Substances 0.000 abstract 2
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000000732 arylene group Chemical group 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 229940061607 dibasic sodium phosphate Drugs 0.000 abstract 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000004820 halides Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000005549 heteroarylene group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000005020 hydroxyalkenyl group Chemical group 0.000 abstract 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- -1 oxyalkenyl Chemical group 0.000 abstract 1
- 229920001992 poloxamer 407 Polymers 0.000 abstract 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 abstract 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 abstract 1
- 229920000053 polysorbate 80 Polymers 0.000 abstract 1
- 229940068968 polysorbate 80 Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000011780 sodium chloride Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26789709P | 2009-12-09 | 2009-12-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR078929A1 true AR078929A1 (es) | 2011-12-14 |
Family
ID=43503864
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100104122A AR078929A1 (es) | 2009-12-09 | 2010-11-05 | Composicion que comprende un ester de un prostanoide y un acido carboxilico. metodo para conferir estabilidad acuosa a la anterior y su uso para preparar un medicamento util para tratar un trastorno ocular |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20110136872A1 (enExample) |
| EP (1) | EP2509582A1 (enExample) |
| JP (2) | JP5955774B2 (enExample) |
| KR (1) | KR20120106788A (enExample) |
| CN (1) | CN102762195B (enExample) |
| AR (1) | AR078929A1 (enExample) |
| AU (1) | AU2010328555B2 (enExample) |
| CA (1) | CA2783707A1 (enExample) |
| CL (1) | CL2012001545A1 (enExample) |
| IL (1) | IL220240A0 (enExample) |
| MX (1) | MX2012006622A (enExample) |
| NZ (1) | NZ600577A (enExample) |
| RU (1) | RU2012127869A (enExample) |
| SG (1) | SG181600A1 (enExample) |
| TW (1) | TW201138766A (enExample) |
| WO (1) | WO2011071620A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR201900863T4 (tr) | 2012-08-27 | 2019-02-21 | Allergan Inc | Beta-klorosiklopentanların hidrofilik ester ön ilaçlarının kullanılmasıyla merkezi korneal kalınlaşmanın azaltılması. |
| KR101535825B1 (ko) | 2012-09-25 | 2015-07-10 | 엘지디스플레이 주식회사 | 표시장치 및 이의 라인결함 검출방법 |
| KR20160124835A (ko) * | 2014-02-20 | 2016-10-28 | 알러간, 인코포레이티드 | 베타-클로로시클로펜탄의 친수성 에스테르 프로드럭의 사용에 의해 감소된 중앙 각막 비후 |
| US10329284B2 (en) | 2014-10-02 | 2019-06-25 | Allergan, Inc. | Ester prodrugs of gamma-lactams and their use |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5034413A (en) | 1989-07-27 | 1991-07-23 | Allergan, Inc. | Intraocular pressure reducing 9,11-diacyl prostaglandins |
| US5028624A (en) * | 1989-07-27 | 1991-07-02 | Allergan, Inc. | Intraocular pressure reducing 9,15-diacyl prostaglandins |
| CA2021316C (en) * | 1989-07-27 | 2000-10-24 | Ming Fai Chan | Intraocular pressure reducing 11-acyl prostaglandins |
| US4994274A (en) * | 1989-07-27 | 1991-02-19 | Allergan, Inc. | Intraocular pressure reducing 11,15-diacyl prostaglandins and method of using |
| WO2000004898A1 (en) * | 1998-07-21 | 2000-02-03 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
| DK1321144T3 (da) * | 2000-09-13 | 2011-03-07 | Santen Pharmaceutical Co Ltd | Øjendråber |
| ATE374031T1 (de) * | 2002-08-23 | 2007-10-15 | Santen Pharmaceutical Co Ltd | Stabile augentropfen enthaltend latanoprost als wirkstoff |
| SI1759702T1 (sl) * | 2004-05-26 | 2009-06-30 | Bayardo Arturo Jimenez | Postopek pripravljanja oftalmiäśne raztopine latanoprosta in tako proizvedena raztopina |
| US20050276867A1 (en) * | 2004-06-09 | 2005-12-15 | Allergan, Inc. | Stabilized compositions comprising a therapeutically active agent and an oxidizing preservative |
| CN105520941B (zh) * | 2005-03-10 | 2020-05-01 | 阿勒根公司 | 作为治疗剂的取代的γ内酰胺 |
| JPWO2008096804A1 (ja) * | 2007-02-07 | 2010-05-27 | テイカ製薬株式会社 | ラタノプロスト含有点眼剤 |
| WO2009132088A1 (en) * | 2008-04-24 | 2009-10-29 | Allergan, Inc. | Substituted gamma lactams as therapeutic agents |
| EP2127638A1 (en) * | 2008-05-30 | 2009-12-02 | Santen Pharmaceutical Co., Ltd | Method and composition for treating ocular hypertension and glaucoma |
-
2010
- 2010-11-04 US US12/939,861 patent/US20110136872A1/en not_active Abandoned
- 2010-11-05 WO PCT/US2010/055590 patent/WO2011071620A1/en not_active Ceased
- 2010-11-05 RU RU2012127869/15A patent/RU2012127869A/ru not_active Application Discontinuation
- 2010-11-05 MX MX2012006622A patent/MX2012006622A/es not_active Application Discontinuation
- 2010-11-05 CN CN201080063225.1A patent/CN102762195B/zh not_active Expired - Fee Related
- 2010-11-05 AU AU2010328555A patent/AU2010328555B2/en not_active Ceased
- 2010-11-05 JP JP2012543111A patent/JP5955774B2/ja not_active Expired - Fee Related
- 2010-11-05 NZ NZ600577A patent/NZ600577A/en not_active IP Right Cessation
- 2010-11-05 EP EP10782082A patent/EP2509582A1/en not_active Withdrawn
- 2010-11-05 AR ARP100104122A patent/AR078929A1/es unknown
- 2010-11-05 KR KR1020127017676A patent/KR20120106788A/ko not_active Ceased
- 2010-11-05 SG SG2012042461A patent/SG181600A1/en unknown
- 2010-11-05 CA CA2783707A patent/CA2783707A1/en not_active Abandoned
- 2010-11-05 TW TW099138227A patent/TW201138766A/zh unknown
-
2012
- 2012-06-07 IL IL220240A patent/IL220240A0/en unknown
- 2012-06-08 CL CL2012001545A patent/CL2012001545A1/es unknown
-
2015
- 2015-08-26 US US14/836,785 patent/US20160220677A1/en not_active Abandoned
-
2016
- 2016-01-14 JP JP2016005576A patent/JP2016056207A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010328555B2 (en) | 2016-05-26 |
| WO2011071620A1 (en) | 2011-06-16 |
| US20110136872A1 (en) | 2011-06-09 |
| RU2012127869A (ru) | 2014-01-20 |
| KR20120106788A (ko) | 2012-09-26 |
| SG181600A1 (en) | 2012-07-30 |
| MX2012006622A (es) | 2012-08-15 |
| JP5955774B2 (ja) | 2016-07-20 |
| TW201138766A (en) | 2011-11-16 |
| EP2509582A1 (en) | 2012-10-17 |
| JP2016056207A (ja) | 2016-04-21 |
| CA2783707A1 (en) | 2011-06-16 |
| NZ600577A (en) | 2014-10-31 |
| US20160220677A1 (en) | 2016-08-04 |
| CL2012001545A1 (es) | 2012-08-31 |
| IL220240A0 (en) | 2012-07-31 |
| CN102762195A (zh) | 2012-10-31 |
| AU2010328555A1 (en) | 2012-07-05 |
| CN102762195B (zh) | 2016-05-18 |
| JP2013513606A (ja) | 2013-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102804061B1 (ko) | 아트로핀-함유 수성 조성물 | |
| AR078929A1 (es) | Composicion que comprende un ester de un prostanoide y un acido carboxilico. metodo para conferir estabilidad acuosa a la anterior y su uso para preparar un medicamento util para tratar un trastorno ocular | |
| PE20051052A1 (es) | Derivados nitrooxi de prostaglandinas | |
| ES2331313T3 (es) | Composicion farmaceutica que contiene prostaglandina. | |
| AR047669A1 (es) | Entidad seleccionada entre un compuesto de xantina y un derivado fisiologicamente funcional del mismo, su uso para la fabricacion de un medicamento, formulacion farmaceutica y combinacion de formulaciones que la comprenden y metodo para su preparacion | |
| JP2016065095A5 (enExample) | ||
| RU2010142307A (ru) | Фармацевтические композиции, обладающие желаемой биодоступностью | |
| NO20074390L (no) | Forsterket bimatoprost oye-opplosning | |
| HRP20110801T1 (hr) | Tekući oblik fsh | |
| MX2021002935A (es) | Formulacion de anticuerpos contra csf-1r. | |
| CO2020009992A2 (es) | Composiciones oftálmicas que comprenden bilastina, una beta-ciclodextrina y al menos un agente de gelificación | |
| BRPI0606606A2 (pt) | composições estáveis contendo prostaglandina | |
| JP2013508383A (ja) | 瞳孔拡張を調節するための、フェントラミンを含む組成物及び方法 | |
| WO2012163827A2 (en) | Ophthalmic preparation comprising a pgf2alpha analogue | |
| PE20071019A1 (es) | Formulaciones farmaceuticas liquidas y semi-solidas que comprenden un modulador de receptores estrogenicos | |
| CY1110644T1 (el) | 5,6,7-τριυδροξυεπτανοϊκο οξυ και τα αναλογα για την θεραπεια οφθαλμικων ασθενειων που σχετιζονται με υπερεκφυτικες και αγγειογενεις αντιδρασεις | |
| PE20080149A1 (es) | Formulacion liquida acuosa que comprende un beta bloqueador | |
| PE20061348A1 (es) | DERIVADOS DEL ACIDO PIRMIDINCARBOXILICO COMO MODULADORES DE PPAR-alfa | |
| JP2011057717A (ja) | イソプロピルウノプロストンの分解抑制方法 | |
| PE20091526A1 (es) | Derivados del acido fenilacetico como moduladores de la inflamacion | |
| ES2791360T3 (es) | Composiciones oftálmicas que comprenden iota-carragenina | |
| JP2018510855A5 (enExample) | ||
| JP5753958B2 (ja) | 澄明な水性液剤 | |
| JP2011207874A (ja) | ソフトコンタクトレンズ用眼科組成物 | |
| JP2013227300A (ja) | ２−アミノ−３−（４−ブロモベンゾイル）フェニル酢酸含有水性組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |